Why Is GOVX Stock Falling Today?

• GeoVax to focus on the development of its lead vaccine and cancer therapy programs.
• The company also filed a prospectus with the SEC for the resale of up to 7.6 million shares of common stock.
• The vaccine maker added that its current cash and cash equivalents are expected to support operations through August 2026.

Shares of GeoVax Labs (GOVX) plunged 12% on Tuesday as investors reacted to a resale prospectus for more than seven million shares, and the biotech firm’s announcement that it had scrapped development of its COVID-19 vaccine candidate.

GeoVax Labs shares suffered their steepest single-day decline in more than two months, putting the stock on track to snap a blistering three-session rally that had lifted its value by nearly 82%.

GOVX To Focus On Smallpox, Cancer Therapies

GeoVax said it is sharpening its focus on its lead vaccine and cancer therapy programs while discontinuing development of its COVID-19 vaccine candidate, GEO-CM04S1, as demand in the global COVID vaccine market continues to weaken.

The company said the move was not tied to safety concerns but was aimed at prioritizing programs with stronger commercial and regulatory opportunities.

GeoVax will now concentrate resources on GEO-MVA, its mpox and smallpox vaccine candidate, and Gedeptin, its cancer therapy. GEO-MVA is advancing under an expedited regulatory pathway supported by the European Medicines Agency (EMA) and could move toward commercialization following a planned Phase 3 study.

Meanwhile, Gedeptin is being developed alongside immunotherapy treatments for head and neck cancers.

7.6M Share Resale

GeoVax also filed a prospectus with the SEC on Tuesday for the resale of up to 7.6 million shares of common stock tied to warrant exercises and a private placement completed earlier this month.

The company said it will not receive any proceeds from the resale of the shares, but could receive cash proceeds if investors exercise the outstanding warrants. On May 18, the company raised about $2.7 million through a private placement.

GeoVax also added that its current cash and cash equivalents are expected to support operations through August 2026.

What Does Retail Think Of GOVX?

Despite the decline, retail sentiment for GOVX on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.

One user said any chance of a rally is ‘dead’ after the firm significantly increased its free float. According to Koyfin data, the company has 2.89 million shares outstanding.

The stock has declined more than 22% so far in 2026.

Read also: GRRR’s New Deal Comes With A $2B Revenue Potential – Third Data Center Infra Deal In A Month Gets Retail Eyeing $100 Mark For The Stock

For updates and corrections, email newsroom[at]stocktwits[dot]com.